Tradestie Institutional Equity Comparison Engine

CLYM vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CLYM N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -62.7%
Momentum & Technical Winner CLYM
1Y +414.7% vs -73.8% ยท 52W Pos 49% vs 14%
Options & Structure Winner CLYM
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap $608.5M
1M Return +0.51%
1Y Return +414.74%
Forward P/E N/M
Unified AI Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
1M Return +12.12%
1Y Return -73.76%
Forward P/E 23.0x
Unified AI Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +414.74% CVM -73.76% Spread: +486.79 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% CVM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs CVM. Trailing 12-month operating profitability (CLYM 0.0% vs CVM 0.0%) and valuation multiples (CLYM N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (6) vs CVM (2)
Institutional Metric CLYM CVM Criterion Row Winner
Market Capitalization Scale $608.5M $22.5M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth +0.0% -62.7% Higher Growth CLYM
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -252.5% Higher ROE CLYM
52-Week Range Position Momentum 49% ($2โ€“$18) 14% ($1โ€“$8) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 112% Vol 0.42ฮฒ ยท 140% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 45.7 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs CVM Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.